<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-08-08T20:59:13Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DocumentandEntityInformation" roleURI="http://www.iderapharma.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.iderapharma.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.iderapharma.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_StatementOfIncome" roleURI="http://www.iderapharma.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.iderapharma.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureOrganizationAdditionalInformation" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureOrganizationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureCashAndCashEquivalentsAdditionalInformation" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureFairValueOfAssetsAndLiabilitiesAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasis" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureFairValueOfAssetsAndLiabilitiesAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureInvestmentsSummaryOfAvailableforSaleInvestmentsAtFairValue" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureInvestmentsSummaryOfAvailableforSaleInvestmentsAtFairValue"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureInvestmentsAdditionalInformation" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureInvestmentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosurePropertyAndEquipmentTabularDisclosureOfMajorComponentsOfPropertyAndEquipmentAndRelatedAccumulatedDepreciation" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosurePropertyAndEquipmentTabularDisclosureOfMajorComponentsOfPropertyAndEquipmentAndRelatedAccumulatedDepreciation"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureRestrictedCashAdditionalInformation" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureRestrictedCashAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureCollaborationsAdditionalInformation" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureCollaborationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureComprehensiveIncomeLossChangesInAccumulatedBalanceOfTheComponentOfOtherComprehensiveGainLoss" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureComprehensiveIncomeLossChangesInAccumulatedBalanceOfTheComponentOfOtherComprehensiveGainLoss"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureComprehensiveIncomeLossAdditionalInformation" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureComprehensiveIncomeLossAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDuringPeriod" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDuringPeriod"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureNetLossPerCommonShareApplicableToCommonStockholdersAdditionalInformation" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureNetLossPerCommonShareApplicableToCommonStockholdersAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureCommonStockWarrantAndOptionExercisesAndEmployeeStockPurchasesAdditionalInformation" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureCommonStockWarrantAndOptionExercisesAndEmployeeStockPurchasesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureFinancingAdditionalInformation1" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureFinancingAdditionalInformation1"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureFinancingAdditionalInformation2" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureFinancingAdditionalInformation2"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureFinancingMay2013FollowonUnderwrittenPublicOffering" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureFinancingMay2013FollowonUnderwrittenPublicOffering"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#DisclosureFinancingAdditionalInformation3" roleURI="http://www.iderapharma.com/taxonomy/role/DisclosureFinancingAdditionalInformation3"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlockPolicies" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsCondensedFinancialStatementsTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsCondensedFinancialStatementsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsCashAndCashEquivalentsDisclosureTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsCashAndCashEquivalentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsRestrictedAssetsDisclosureTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsRestrictedAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsComprehensiveIncomeNoteTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsComprehensiveIncomeNoteTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsComprehensiveIncomeNoteTextBlockTables" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsComprehensiveIncomeNoteTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsCommonStockWarrantAndOptionExercisesAndEmployeeStockPurchasesTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsCommonStockWarrantAndOptionExercisesAndEmployeeStockPurchasesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsSaleOfCommonAndPreferredStockAndWarrantsTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsSaleOfCommonAndPreferredStockAndWarrantsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsSaleOfCommonAndPreferredStockAndWarrantsTextBlockTables" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsSaleOfCommonAndPreferredStockAndWarrantsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="idra-20140630.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeNet" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SalesRevenueNet" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1.0400" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <loc xlink:type="locator" xlink:href="idra-20140630.xsd#idra_PaymentsOfDividendsPreferredStock" xlink:label="idra_PaymentsOfDividendsPreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity"/>
    <loc xlink:type="locator" xlink:href="idra-20140630.xsd#idra_ProceedsFromSaleOfCommonStockAndWarrantsNetOfIssuanceCosts" xlink:label="idra_ProceedsFromSaleOfCommonStockAndWarrantsNetOfIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="idra_ProceedsFromSaleOfCommonStockAndWarrantsNetOfIssuanceCosts" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="idra_PaymentsOfDividendsPreferredStock" order="1.1500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromOtherEquity" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_OtherNoncashExpense" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.0800" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureOrganizationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureFairValueOfAssetsAndLiabilitiesAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasis">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureInvestmentsSummaryOfAvailableforSaleInvestmentsAtFairValue">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="idra-20140630.xsd#idra_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" xlink:label="idra_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="idra-20140630.xsd#idra_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="idra_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="idra_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="idra_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureInvestmentsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosurePropertyAndEquipmentTabularDisclosureOfMajorComponentsOfPropertyAndEquipmentAndRelatedAccumulatedDepreciation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="idra-20140630.xsd#idra_LaboratoryEquipmentAndOtherFixedAssetsGross" xlink:label="idra_LaboratoryEquipmentAndOtherFixedAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_LeaseholdImprovementsGross" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="idra_LaboratoryEquipmentAndOtherFixedAssetsGross" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0400" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureRestrictedCashAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureCollaborationsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureComprehensiveIncomeLossChangesInAccumulatedBalanceOfTheComponentOfOtherComprehensiveGainLoss">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureComprehensiveIncomeLossAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDuringPeriod">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureNetLossPerCommonShareApplicableToCommonStockholdersAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureCommonStockWarrantAndOptionExercisesAndEmployeeStockPurchasesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureFinancingAdditionalInformation1">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureFinancingAdditionalInformation2">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureFinancingMay2013FollowonUnderwrittenPublicOffering">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/DisclosureFinancingAdditionalInformation3">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsCondensedFinancialStatementsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsCashAndCashEquivalentsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsRestrictedAssetsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsComprehensiveIncomeNoteTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsComprehensiveIncomeNoteTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsCommonStockWarrantAndOptionExercisesAndEmployeeStockPurchasesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsSaleOfCommonAndPreferredStockAndWarrantsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsSaleOfCommonAndPreferredStockAndWarrantsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.iderapharma.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>


